Kineticos Ventures

Frank Lis, the founder, serves as President and CEO and is the central decision-maker on investments. The firm operates with a flat structure, and its team draws heavily from the Kineticos Life Sciences consultancy, giving clinical and regulatory experts direct input into deal evaluation.

Kineticos Life Sciences is an established life-science advisory firm that predates or operates alongside the Ventures arm. The consultancy generates revenue from biotech and diagnostics companies on strategy, market access, and M&A mandates. That revenue stream reduces reliance on management fees, and advisory clients periodically become investment prospects or co-development partners for portfolio companies.

No. While the firm is anchored in Raleigh and draws significant deal flow from the university and hospital networks of North Carolina's Research Triangle, its investments and advisory engagements are national. It has also evaluated opportunities in European biotech, particularly firms seeking US commercialization pathways.

The firm concentrates on seed and early-stage rounds, where scientific assets have emerged from academic labs or initial preclinical work but lack the commercial infrastructure to advance. It frequently gets involved before a traditional Series A syndicate forms, providing capital and operational scaffolding concurrently.

The firm has not publicly disclosed its fund structure or whether capital is deployed from a committed blind-pool fund, a series of SPVs, or a hybrid evergreen vehicle. Its public posture emphasizes the integrated consultancy, which distinguishes its economics from a typical closed-end venture fund.